March 27th 2025, 9:00pm
By Ryan Scott
March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.
March 27th 2025, 8:53pm
By Georgina Long
The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.
March 27th 2025, 7:00pm
By Alex Biese
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
March 27th 2025, 5:00pm
By Bonnie Annis
Cancer memories often sneak up on me when I least expect them to.
March 27th 2025, 4:00pm
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.
March 27th 2025, 3:00pm
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.
March 27th 2025, 1:00pm
By Dr. Elizabeth K. Lee
Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study.
March 26th 2025, 9:00pm
Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with recurrent glioblastoma.
March 26th 2025, 8:00pm
Sid Sadler discusses kidney cancer awareness, patient advocacy and the need for specialized care to improve access to treatments and clinical trials.
March 26th 2025, 7:00pm
A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient Multiple Myeloma Summit.
March 26th 2025, 5:00pm
By Felicia Mitchell
Survivors facing new medical concerns may fear the unknown, but perseverance is possible as they navigate unexpected challenges in their new normal.
March 26th 2025, 4:00pm
By Spencer Feldman
A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral doses.
March 26th 2025, 1:44pm
The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
March 26th 2025, 1:00pm
Melissa Ursini discussed her experience with a colorectal cancer diagnosis at age 37, highlighting her insights during Colorectal Cancer Awareness Month.
March 25th 2025, 9:00pm
The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.
Bringing Together the CAR T-Cell Therapy Community
Nutrition is Key Following a Cancer Diagnosis
The Leukemia & Lymphoma Society is Helping Patients With Medial Debt
Insights into the Latest Trends in Pancreatic Cancer